{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T09:40:45Z","timestamp":1698831645865},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T00:00:00Z","timestamp":1334016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytopathology"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:p>N. Gupta, N. Dudding, J. Crossley, S.J. Payyappilly and J.H.F. Smith \u2028<jats:bold>Outcome of SurePath\u2122 cervical samples reported as borderline nuclear changes by cytological subtype and high\u2010risk HPV status<\/jats:bold><\/jats:p><jats:p><jats:bold>Background:\u2002<\/jats:bold> The average borderline rate in cervical cytology samples for English laboratories was 3.8% with the range being 2.0\u20136.8% at the time of the present study, which was undertaken in order to determine the association between different subtypes of borderline nuclear change (BNC), high\u2010grade cervical intraepithelial neoplasia (CIN) and high\u2010risk human papillomavirus (hrHPV) status.<\/jats:p><jats:p><jats:bold>Materials and methods:\u2002<\/jats:bold> Of 68 551 SurePath<jats:sup>TM<\/jats:sup> cervical samples reported in one laboratory over a period of 2\u2003years, 2335 (3.4%) were reported as BNC. hrHPV status was known in 1112 cases (47.6%). The outcome was known only for women with hrHPV\u2010positive BNC, who were recommended for colposcopy under the National Health Service Cervical Screening Programme sentinel site protocol. Women with hrHPV\u2010negative BNC were returned to 3\u2010yearly recall. The cases were subdivided into BNC, high\u2010grade dyskaryosis cannot be excluded (B\u2010HG; 105 cases); BNC with koilocytosis (B\u2010K; 421 cases); BNC with other features of HPV (B\u2010HPV; 160 cases); and BNC, not otherwise specified (B\u2010NOS; 426 cases) and were correlated with the histological outcome where available.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> The study population age ranged from 23 to 65\u2003years. Cases that tested positive for hrHPV by Qiagen HCII assay comprised 78.1%, 81.0%, 73.1% and 67.8% of B\u2010HG, B\u2010K, B\u2010HPV and B\u2010NOS categories, respectively. CIN2 or worse (CIN2+) was found in 64.6%, 10.0%, 19.7% and 20.1% of hrHPV\u2010positive cases of B\u2010HG, B\u2010K, B\u2010HPV and B\u2010NOS, respectively, which was significantly higher in the B\u2010HG category (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001) and lower in the B\u2010K category compared with B\u2010NOS (p\u2003&lt;\u20030.001) and B\u2010HPV (p\u2003=\u20030.006) respectively. CIN3+ comprised 55.6%, 6.3%, 26.3% and 19.1% of biopsies in the same categories, respectively.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Subtyping BNC is useful, especially B\u2010K and B\u2010HG, which, respectively, had the lowest and highest rates of detection of both CIN2+ and CIN3+, confirming that koilocytosis is likely to be associated with transient HPV infection. Women with B\u2010HG should be referred to colposcopy in the absence of HPV triage.<\/jats:p>","DOI":"10.1111\/j.1365-2303.2012.00976.x","type":"journal-article","created":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T04:09:28Z","timestamp":1334030968000},"page":"402-407","source":"Crossref","is-referenced-by-count":1,"title":["Outcome of SurePath\u2122 cervical samples reported as borderline nuclear change by cytological subtype and high\u2010risk HPV status"],"prefix":"10.1111","volume":"23","author":[{"given":"N.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Dudding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Crossley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. J.","family":"Payyappilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H. F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,10]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.39.9.933"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.47.6.481"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.16.2114"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/dc.10303"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/dc.20227"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2010.00780.x"},{"key":"e_1_2_5_8_2","article-title":"Borderline\u2003nuclear\u2003change,\u2003high\u2010grade\u2003dyskaryosis\u2003not excluded: current concepts and impact on clinical practice","author":"Soo Hoo S","year":"2011","journal-title":"Cytopathology"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2003.00118.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2008.00585.x"},{"key":"e_1_2_5_11_2","unstructured":"JohnsonJ PatnickJ(eds).Achievable standards Benchmarks for reporting and Criteria for evaluating cervical cytopathology NHSCSP Publication No. 1 May 2000. Available fromhttp:\/\/www.cancerscreening.nhs.uk\/cervical\/csp01.pdf. Last accessed on 19.1.12."},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1699-0463.1992.tb00872.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2303.1996.37282372.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2007.00548.x"},{"key":"e_1_2_5_15_2","unstructured":"HPV Sentinel Sites Implementation Project.NHS Cervical Screening Programme Available athttp:\/\/www.cancerscreening.nhs.ukLast accessed 5 July 2011."},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.1993.tb00112.x"},{"key":"e_1_2_5_17_2","volume-title":"Guidelines for the NHS Cervical Screening Programme","author":"Luesley D","year":"2010"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90178-9"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004347-198609000-00006"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.52.10.787"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.304.6836.1209"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6629.1099"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.1992.tb00030.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2303.2002.00395.x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.5858\/2003-127-946-FTDFTA"},{"key":"e_1_2_5_26_2","unstructured":"MossSM GrayA LegoodR HenstockEEvaluation of HPV\/LBC Cervical screening pilot studies First report to Department of Health on evaluation LBC (December 2002) http:\/\/www.cancerscreening.nhs.uk\/cervical\/lbc\u2010pilot\u2010evaluation.pdf."},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.01.008"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.4.293"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1309\/JM3V-U4HP-W8HJ-68XV"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.1993.tb00102.x"},{"key":"e_1_2_5_31_2","article-title":"PCR study of a series of ASCUS cases HPV\u2010positive by HCII","author":"Alameda F","year":"2011","journal-title":"Diagn Cytopathol"}],"container-title":["Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2303.2012.00976.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2303.2012.00976.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T06:59:47Z","timestamp":1698735587000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2303.2012.00976.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,10]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/j.1365-2303.2012.00976.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2303.2012.00976.x","archive":["Portico"],"relation":{},"ISSN":["0956-5507","1365-2303"],"issn-type":[{"value":"0956-5507","type":"print"},{"value":"1365-2303","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,10]]}}}